Advertisement

Topics

FDA expands use of AZ/Merck’s Lynparza in the US

04:31 EDT 18 Aug 2017 | PharmaTimes

AstraZeneca and Merck & Co’s Lynparza will be available to a wider range of patients in the US after regulators expanded the PARP inhibitor’s list of approved uses.

Original Article: FDA expands use of AZ/Merck’s Lynparza in the US

NEXT ARTICLE

More From BioPortfolio on "FDA expands use of AZ/Merck’s Lynparza in the US"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...